Key Points
- Major shareholder Adar1 Capital Management bought 79,259 Rallybio shares at an average price of $13.99, a transaction worth about $1.11 million. After the purchase, it owned 909,843 shares, boosting its stake by 9.54%.
- Adar1 has been aggressively adding to its position with several recent buys, including 120,804 shares on May 4 and 50,000 shares on May 11. The recent activity suggests sustained insider confidence in the stock.
- Rallybio’s latest earnings missed expectations, with a quarterly loss of $1.46 per share versus a $1.20 estimate, while analysts still rate the stock an average of Sell. Despite this, the shares have risen sharply from their 1-year low and recently traded near their 1-year high.
Rallybio Corporation (NASDAQ:RLYB - Get Free Report) major shareholder Adar1 Capital Management, Llc bought 79,259 shares of the company's stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average cost of $13.99 per share, for a total transaction of $1,108,833.41. Following the completion of the acquisition, the insider owned 909,843 shares of the company's stock, valued at $12,728,703.57. This trade represents a 9.54% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Adar1 Capital Management, Llc also recently made the following trade(s):
- On Friday, May 15th, Adar1 Capital Management, Llc bought 300 shares of Rallybio stock. The shares were bought at an average cost of $13.90 per share, for a total transaction of $4,170.00.
- On Tuesday, May 12th, Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock. The shares were acquired at an average price of $13.83 per share, for a total transaction of $11,064.00.
- On Monday, May 11th, Adar1 Capital Management, Llc purchased 50,000 shares of Rallybio stock. The shares were acquired at an average price of $14.00 per share, for a total transaction of $700,000.00.
- On Tuesday, May 5th, Adar1 Capital Management, Llc purchased 35,101 shares of Rallybio stock. The shares were acquired at an average price of $14.00 per share, for a total transaction of $491,414.00.
- On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The shares were acquired at an average price of $13.97 per share, for a total transaction of $1,687,631.88.
Rallybio Price Performance
NASDAQ RLYB opened at $14.30 on Friday. The company has a market cap of $75.65 million, a PE ratio of -3.14 and a beta of -1.10. The stock's 50 day simple moving average is $9.84 and its 200-day simple moving average is $7.05. Rallybio Corporation has a 1-year low of $2.16 and a 1-year high of $15.31.
Rallybio (NASDAQ:RLYB - Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.26). The firm had revenue of $0.21 million during the quarter, compared to analysts' expectations of $0.21 million. Rallybio had a negative net margin of 911.07% and a negative return on equity of 55.79%.
Analyst Ratings Changes
Several equities research analysts have issued reports on the company. Wall Street Zen raised Rallybio to a "hold" rating in a research note on Saturday, March 28th. Weiss Ratings reissued a "sell (d-)" rating on shares of Rallybio in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of "Sell".
Get Our Latest Report on Rallybio
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of RLYB. XTX Topco Ltd lifted its holdings in Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock worth $67,000 after buying an additional 38,205 shares during the last quarter. Susquehanna International Group LLP lifted its holdings in Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock worth $68,000 after buying an additional 113,031 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock worth $170,000 after buying an additional 2,996 shares during the last quarter. Citadel Advisors LLC lifted its holdings in Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock worth $219,000 after buying an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock worth $573,000 after buying an additional 120,892 shares during the last quarter. 90.34% of the stock is owned by institutional investors and hedge funds.
About Rallybio
(
Get Free Report)
Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.
Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
